Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: Formulation, characterization and pharmacodynamic study

Scientia Pharmaceutica

Volumn 79, Issue 3, 2011, Pages 635-651

  Detroja, Chetan ^a   Chavhan, Sandip ^a   Sawant, Krutika ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Bioavailability; Candesartan; DOCA salt model; Nanosuspension; Saturation solubility

Indexed keywords

CANDESARTAN; DEOXYCORTICOSTERONE ACETATE; PHOSPHATE BUFFERED SALINE;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; FEMALE; HYPERTENSION; IN VIVO STUDY; NANOSUSPENSION; NONHUMAN; PARTICLE SIZE; PH; PHARMACODYNAMICS; RAT; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

EID: 80051738719     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1103-17     Document Type: Article

References (35)

1. Mizno K, Niimura S, Tani M, Saito J, Sanada H, Takakashi M. Hypotensive activity of TV-116, a newly developed angiotensin II receptor antagonist in spontaneously hypertensive rats. Life Sci. 1992; 51: 183-187. doi:10.1016/0024-3205(92)90627-2
2. Delacretaz E, Nussberger J, Biollaz J, Waeber B, Brunner H. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension. 1995; 25: 14-21. PMid:7843746
3. Bertil A, Jonas O. Pharmaceutical composition comprising candesartan cilexetil. WO 030161 A1 patent (2008).
4. Product monograph. ATACAND® Candesartan cilexetil tablets, AstraZeneca Canada Inc., Ontario.
5. Stella VJ, Rajewski RA. Cyclodextrin: their future in drug formulation and delivery. Pharm Res. 1997; 14: 556-567. doi:10.1023/A:1012136608249
6. Akers MJ. Excipient-drug interactions in parenteral formulations. J Pharm Sci. 2002; 91: 2283-2300. doi:10.1002/jps.10154
7. Floyd AG. Top ten considerations in the development of parenteral emulsions. Pharm Sci Tech Today. 1999; 2: 134-143. doi:10.1016/S1461-5347(99)00141-8
8. Nakano M. Places of emulsions in drug delivery. Adv Drug Deliv Rev. 2000; 45: 1-4. doi:10.1016/S0169-409X(00)00096-X
9. Sigfridsson K, Forssen S, Hollander P, Skantze U, Verdier J. A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound. Eur J Pharm Biopharm. 2007; 67: 540-547. doi:10.1016/j.ejpb.2007.02.008
10. Hargrove JT, Maxson WS, Wentz AC. Absorption of oral progesterone is influenced by vehicle and particle size. Am J Obstet Gynecol. 1989; 161: 948-951. PMid:2801843
11. Nekkanti V, Pillai R, Venkateshwarlu V, Harisudhan T. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles. Pharm Dev Technol. 2009; 14: 290-298. doi:10.1080/10837450802585278
12. Liversidge GG, Cundy K. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995; 125: 91-97. doi:10.1016/0378-5173(95)00122-Y
13. Liversidge GG, Conzentino P. Drug particle reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm. 1995; 125: 309-313. doi:10.1016/0378-5173(95)00148-C
14. Jia L, Wong J, Cerna C, Weitman S. Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm Res. 2002; 19: 1091-1096. doi:10.1023/A:1019829622088
15. HS Nalwa (ed.). Drug nanocrystals of poorly soluble drugs. In: Encyclopedia of Nanoscience and Nanotechnology. American Scientific Publishers: Los Angels, 2004: 627-638.
16. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001; 47: 3-19. doi:10.1016/S0169-409X(00)00118-6
17. Liversidge GG, Cundy KC, Bishop JF, Czekai DA. Surface modified drug nanoparticles. U.S.Patent 5145684 (1991).
18. Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U. Amorphous Drug Nanosuspensions 1.Inhibition of Ostwald Ripening. Langmuir. 2006; 22: 906-910. doi:10.1021/la0523661
19. Mauludin R. Nanosuspension of poorly soluble drugs for oral administration. Dissertation, Free University of Berlin (2008).
20. Eerdenbrugh BV, Mooter GV, Augustijns P. Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008; 364: 64-75. doi:10.1016/j.ijpharm.2008.07.023
21. Eerdenbrugh BV, Froyen L, Martens JA, Blaton N, Augustijns P, Brewster M. Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int J Pharm. 2007; 338: 198-206. doi:10.1016/j.ijpharm.2007.02.005
22. Chaubal MV, Popescu C. Conversion of Nanosuspensions into Dry Powders by Spray Drying: A Case Study. Pharm Res. 2008; 25: 2302-2308. doi:10.1007/s11095-008-9625-0
23. http://www.accessdata.fda.gov/scripts/cder/dissolution/candesartan (Accessed on 13march 2009)
24. Israili ZH. Clinical pharmacokinetics of angiotensin II [AT1] receptor blockers in hypertension. J Hum Hypertens. 2000; 14: 73-86. doi:10.1038/sj.jhh.1000991
25. McClellan KJ, Goa KL. Candesartan cilexetil: a review of its use in essential hypertension. Drugs. 1998; 56: 847-869. doi:10.2165/00003495-199856050-00013
26. Takaoka M, Kobayashi Y, Yuba M, Ohkita M, Matsumura Y. Effect of α- lipoic acid in deoxycorticostorone acetate-salt-induced hypertension in rats. Eur J Pharmacol. 2001; 424: 121-129. doi:10.1016/S0014-2999(01)01120-7
27. Shirai K, Watanabe K, Ma M, Wahed M, Inoue M, Saito Y. Effects of angiotensin-II receptor blocker candesartan cilexetil in rats with dilated cardiomyopathy. Mol Cell Biochem. 2005; 269: 137-142. doi:10.1007/s11010-005-3446-9
28. Muller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int J Pharm. 1998; 160: 229-237. doi:10.1016/S0378-5173(97)00311-6
29. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 2004; 56: 827-840. doi:10.1211/0022357023691
30. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev. 1995; 17: 31-48. doi:10.1016/0169-409X(95)00039-A
31. Gupta RB, Kompella UB (eds). Manufacturing of nanoparticles by milling and homogenization techniques. In: Nanoparticle Technology for Drug Delivery, Drugs and the Pharmaceutical Sciences. Vol. 159, Taylor & Francis Group: New York, 2006: 21-51.
32. Buckton G, Beezer AE. The relationship between particle size and solubility. Int J Pharm. 1992; 82: 7-10. doi:10.1016/0378-5173(92)90184-4
33. Hirokazu M, Taro E, Koji N, Toshio E, Kazumichi S, Nobuo N. Solid-State Characterization of Candesartan Cilexetil [TCV-116]: Crystal Structure and Molecular Mobility. Chem Pharm Bull. 1999; 47: 182-186.
34. Müller RH, Keck MC. Challenges and solutions for the delivery of biotech drugs-A review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 2004; 113: 151-170. doi:10.1016/j.jbiotec.2004.06.007
35. Pardieke J, Müller RH. Nanosuspensions: A promising formulation for the new phospholipase A2 inhibitor PX-18. Int J Pharm. 2010; 391: 322-329. doi:10.1016/j.ijpharm.2010.03.002